Beeline Medicines raised €42.6 million as it advanced afimetoran in lupus and continued clinical development across its candidate pipeline, marking a clear continued appetite for immunology programs tied to defined clinical endpoints. In parallel, multiple large financings signaled improved resilience in med-tech and biotech capital markets versus prior low-volume periods. For operators, the message was that investor underwriting remains strongest where assets show trial-ready progress and measurable readouts.